Amarin Corporation, the manufacturer of Vascepa, a prescription medication used to lower triglyceride levels in adults, has recently made the switch to generic Vascepa. This decision was likely prompted by the expiration of Amarin's patent on Vascepa in September 2020 [1]. With the expiration of the patent, generic versions of Vascepa were able to enter the market, which could potentially cut into Amarin's profits [2]. In response to this competition, Amarin has revamped its Vascepa strategy, which includes cutting over 400 U.S. sales reps [2]. This move is likely an attempt to reduce costs and increase profitability in the face of generic competition. Humana, a health insurance provider, reported that the generic version of Vascepa is now available to its members, indicating that the switch to generic has been implemented [3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/pharma/faced-generic-foes-amarin-chops-over-400-u-s-sales-reps-as-part-revamped-vascepa-strategy
[3] https://www.humana.com/provider/news/pharmacy-news